STATURE

Treatment tested

• Cladribine

  DNA inhibitor

• Dimethyl fumarate

  Kelch-like ECH-associated protein 1 inhibitor

• Fingolimod
• Teriflunomide

  Dihydroorotate dehydrogenase inhibitor

• Ozanimod

  Sphingosine 1-phosphate receptor 5 modulator

• Diroximel fumarate

  Kelch-like ECH-associated protein 1 inhibitor

Other measures (1)

Inclusion Criteria: * 18 years or older. * A confirmed diagnosis of multiple sclerosis. * Commencement (switching or newly prescribed) of one of the 6 following DMTs within the previous 2-months: cladribine, dimethyl fumarate, fingolimod, teriflunomide, ozanimod, diroximel fumarate. * Able to read and write in English. * Access to an internet connection and computer facilities, required to complete assessments. Exclusion Criteria: * Use of any other DMT than cladribine, dimethyl fumarate, fingolimod, teriflunomide, ozanimod, diroximel fumarate. * Comorbid neurological condition. * Severe cognitive or psychological dysfunction deemed to interfere with the person's ability to undertake study requirements, as determined by their MS clinic treatment team (neurologist; MS nurse).

STATURE is a prospective observational six-arm translation multi-site study that will run for approx. 4.5 years. The primary aim is to measure treatment burden and its relationship to medication adherence across six self-administered oral disease-modifying therapies (cladribine, dimethyl fumarate, fingolimod, teriflunomide, ozanimod, and diroximel fumarate) in multiple sclerosis (MS). The information gained will assist prescribing decision-making; accounting for medication burden at a patient level and potential implications on medication adherence and persistence, thus minimising primary and secondary healthcare costs. Three-hundred and twenty-three individuals with MS will be recruited into the study. Patient-reported outcome measures will be administered via Qualtrics, a secure online data collection tool. Medicare and pharmaceutical benefits scheme (PBS) data will also be collected.